Endonovo Announces Binding Letter of Intent to Sell SofPulse® Assets to Spin-Off Company
Los Angeles, CA, March 29, 2023 (GLOBE NEWSWIRE) — Endonovo Therapeutics Inc. (OTCQB:ENDV) today announced a binding Letter of Intent (LOI) to spin off its current medical device division to an entity controlled by Ira Weisberg, who will be the future President and CEO of a newly formed publicly-traded Delaware company, tentatively named SofPulse, Inc.
Related news for (ENDV)
- Endonovo Closes Asset Purchase Agreement for a Minimum of $50M With SofPulse, Inc
- Endonovo’s SofPulse® to Be Featured at Innovative Pain Management Solutions
- Endonovo Signs Definitive Agreement to Sell SofPulse® Brand Business and IP to SofPulse Inc. for a minimum of $50 Million
- Endonovo’s SofPulse® Secures Taiwan FDA Approval
- Endonovo’s SofPulse® Secures Federal Supply Schedule Inclusion to Accelerate Expansion of VA Distribution